Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-08-16
2011-08-16
Fetterolf, Brandon (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S201000
Reexamination Certificate
active
07998981
ABSTRACT:
The present invention provides aminoaryl sulphonamide derivatives of formula (I), useful in the treatment of a CNS disorder related to or affected by the 5-HT6receptor. Pharmacological profiles of these components include high affinity binding with 5-HT6receptors along with good selectivity towards the receptor. The present invention also includes stereoisomers, the salts, methods of preparation and medicine containing the aminoaryl sulphonamide derivatives.
REFERENCES:
patent: 6774241 (2004-08-01), Clark et al.
patent: WO-9827081 (1998-06-01), None
patent: WO-9902502 (1999-01-01), None
patent: WO-9937623 (1999-07-01), None
patent: WO-9942465 (1999-08-01), None
patent: WO-0132646 (2001-05-01), None
patent: WO-02098878 (2002-12-01), None
patent: WO-03065046 (2003-08-01), None
patent: WO-03066056 (2003-08-01), None
patent: WO-03072548 (2003-09-01), None
patent: WO-2004035047 (2004-04-01), None
patent: WO-2004048328 (2004-06-01), None
patent: WO-2004048330 (2004-06-01), None
patent: WO-2004048331 (2004-06-01), None
patent: WO-2004055026 (2004-07-01), None
patent: WO 2005/025558 (2005-03-01), None
Lindner et al. An assessment of the effects of serotonin 6 (5-HT6) receptor antagonists in rodent models of learning. The Journal of Pharmacology and Experimental Therapeutics, 2003, vol. 307, No. 2.
Diagnostic and Statistical Manual of Mental Disorders, Fourth Ed. Text Revision, Chapter on schizophrenia, pp. 297-299, 308-311, American Psychiatric Assn. Pub, 2000.
Patel (Journal of Geriatric Psychiatry and Neurology, vol. 8, 81-95, 1995).
Kar et al., J. Psychiatry Neurosci. vol. 29(6): 427-441, 2004.
Jacobsen et al. (NeuroTherapeutics, vol. 2: 612-626, Oct. 2005).
Lemere et al. (Rejuvenational Research, vol. 9(1): 77-84, 2006).
Monsma, F. J., Jr. et al, “Cloning and Expression of a Novel . . . ”, Molecular Pharmacology, 1993, 43, 320-327, Am Society for Pharm and Experimental Therapeutics, USA.
Kohen, R. et al, “Cloning, Characterization, and Chromosomal . . . ”, Journal of Neurochemistry, 1996, 66, 47-56, Lippincott-Raven Publishers, USA.
Ruat, M. et al, “A Novel Rat Serotonin (5-HT6) Receptor . . . ”, Biochemical Biophysical Research Communications, 1993, 193, 268-276, Academic Press.
Ward, R. P. et al, “Localization of Serotonin Subtype 6 Receptor . . . ”, Neuroscience, 1995, 64, 1105-1111, Elsevier Science Ltd, UK.
Reavill, C. et al, “The Therapeutic Potential of 5-HT6 . . . ”, Current Opinion in Invesigational Drugs, 2001, 2(1):104-109, PharmaPress Ltd.
Gerard, C. et al, “Immuno-localization of serotonin 5-HT6 receptor-like material . . . ”, Brain Research, 1997, 746, 207-219, ,Elsevier Science B.V.
Bentley, J. C. et al, “Investigation of stretching behaviour induced by the selective . . . ”, British Journal of Pharmacology, 1999, 126 (7), 1537-1542, Stockton Press.
Dawson, L. A. et al, “In vivo effects of the 5-HT6 antagonist . . . ”, British Journal of Pharmacology, 2000, 130 (1), 23-26, Macmillan Publishers Ltd.
Rogers, D. C. et al, “The Selective 5HT6 Receptor Antagonist”, Society of Neuroscience, Abstracts, 2000, 26, 680, UK.
Ernst, M. et al, “DOPA Decarboxylase Activity in Attention Deficit . . . ”, Journal of Neuroscience, 1998, 18(15), 5901-5907, Society for Neuroscience, USA.
Branchek, T. A. et al, Annual Reviews in Pharmacology and Toxicology, 2000, 40, 319-334, Annual Reviews, USA.
Stean, T. et al, “Anticonvulsant Properties of the Selective 5-HT6 Receptor . . . ” British Journal of Pharmacology, 1999, 127 Proc. Supplement-131P.
Routledge, C., “Characterization of SB-271046: A Potent . . . ”, British Journal of Pharamacology, 2000, 130, 1606-1612, Macmillan Publishers Ltd.
Roth, B.L. et al., “Binding of Typical and Atypical Agents . . . ”, Journ of Pharm and Experimental Therapeutics, 1994, 268, pp. 1403-1410, Am Society for Pharm and Exp. Ther.
Sleight, J. et al., Neurotransmission, 1995, 11, 1-5.
Sleight, J. et al., “Serotonin ID Research Alert”, 1997, 2(3), 115-118.
Wooley, M.L. et al., “A Role for 5-HT6 Receptors in Retention of Spatial Learning . . . ”, Neuropharmacology, 2001, 41: 210-219, Elsevier Science Ltd.
Principles of Asymmetric synthesis, J. E. Baldwin Ed., Tetrahedron series, 14, 311-316, 2004.
Berge, Stephen et al., “Pharmaceutical Salts”, Journal of Pharmaceutical Sciences, 1977, 66, 1-19.
Greene, T.W., “Protective Groups in Organic Synthesis”, 1991, John Wiley and Sons.
Kask, A. et al., “Neuropeptide Y Y5 Receptor Antagonist CGP71683A . . . ”, European Journal of Pharmacology, 414, 2001, 215-224, Elsevier Science B.V.
Turnbull, A. et. al., “Selective Antagonism of the NPY Y5 Receptor Does Not . . . ”, Diabetes, 51, 2002, 2441-2449.
Ennaceur, A. et al, “A New One-trial Test for Neurobiological Studies of Memory . . . ”, Behavioural Brain Research, 1988, 31, 47-59, Elsevier Science Publishers.
King, M. V. et. al., “5-HT6 Receptor Antagonists Reverse Delay-dependent . . . ”, Neuropharmacology, 2004, 47, 195-204, Elsevier Ltd.
Yamada, N. et al., “Improvement of Scopolamine-induced Memory Impairment . . . ”, Pharmacology, Biochem. and Behaviour, 2004, 78, 787-791, Elsevier Inc.
Linder, M. D. et al., “An Assessment of the Effects of Serotonin 6 . . . ”, Journal of Pharm and Exp. Ther., 2003, 307 (2), 682-691, Am Soc. for Pharm and Exp. Ther., USA.
Callahan, P. M. et al., “Characterization of the Selective 5-HT6 Receptor . . . ”, Abstract, 776.19.2004, Society for Neuroscience, 2004.
Fox, G. B. et al., “Memory Consolidation Induces a Transient and . . . ”, Journal of Neurochemistry, 1995, 65, 6, 2796-2799, Lippincott-Raven Publishers, USA.
Jasti Venkateswarlu
Kambhampati Rama Sastri
Kandikere Nagaraj Vishwottam
Kota Srinivasulu
Ramakrishna Venkata Satya Nirogi
Fetterolf Brandon
IpHorgan Ltd.
Pagonakis Anna
Suven Life Sciences Limited
LandOfFree
Aminoaryl sulphonamide derivatives as functional 5-HT 6... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aminoaryl sulphonamide derivatives as functional 5-HT 6..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aminoaryl sulphonamide derivatives as functional 5-HT 6... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2656542